# Amwell makes grant to new employee under inducement plan
Canonical URL: https://biopharmsignal.com/news/AMWL/amwell-makes-grant-to-new-employee-under-inducement-plan-0750ee5a
Ticker: AMWL
Company: American Well
Source: American Well
Published: 2026-02-18 21:30 EST
## Summary

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled...

## Article Body
Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, announced that on February 18, Amwell made a grant of RSUs of 61,559 shares of its Class A common stock to one new employee. The grant was offered as material inducement to the employee’s employment with Amwell. The RSUs will vest as follows, subject to the employee’s continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date (“Initial Vesting Date”), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first calendar day of the month following the date that is three months following the Initial Vesting Date) for three years until such RSUs are vested in full.

The grant described in this press release was approved by the Compensation Committee of the Amwell’s Board of Directors pursuant to the Amwell’s Inducement Plan and made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08. Amwell is issuing this press release pursuant to Rule 303A.08.

About Amwell Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell platform includes software and services that power many clinical programs from Amwell and our growing number of partners. Our platform allows patients to experience unified, personalized and simple access to diversified clinical programs across the care continuum. As more people seek care online and more clinical programs become available, we offer integrated, future-ready, consistent solutions. The Amwell platform is proven, operating at a large scale, enabling care for millions of patients and their sponsors while delivering dependable outcomes. For almost two decades, Amwell has proudly served some of the largest and most sophisticated healthcare organizations in the U.S. and worldwide. For more information, visit business.amwell.com or LinkedIn .

Media: Press@amwell.com

Investor: Asher Dewhurst amwell@icrhealthcare.com

Notice of Ownership All materials contained herein are the property of American Well Corporation and are copyrighted under United States law and applicable international copyright laws and treaty provisions. The materials contained herein are not work product or "work for hire" on behalf of any third party. The materials contained herein constitute the confidential information of American Well Corporation, except for specific data elements provided by third parties, which are the confidential information of such third parties. The content contained herein results from the application of American Well proprietary processes, analytical frameworks, algorithms, business methods, solution construction aids and templates, all of which are and remain the property of American Well Corporation.

Trademark Notice All of the trademarks, service marks and logos displayed on these materials (the "Trademark(s)") are registered and unregistered trademarks of American Well Corporation or third parties who have licensed their Trademarks to American Well Corporation. Except as expressly stated in these terms and conditions, you may not reproduce, display or otherwise use any Trademark without first obtaining American Well Corporation's written permission.
## Recent Company News
- 2026-07-24 12:00 EST — [Amwell® to report second quarter 2026 operating results](https://biopharmsignal.com/news/AMWL/amwell-to-report-second-quarter-2026-operating-results-05b3d1ab) — Source: American Well
- 2026-05-18 11:05 EST — [Nature Human Behaviour study finds SilverCloud® by Amwell® reduced prevalence of mental disorders over two years at scale](https://biopharmsignal.com/news/AMWL/nature-human-behaviour-study-finds-silvercloud-by-amwell-reduced-prevalence-of-m-dd7dd711) — Source: American Well
- 2026-05-11 20:05 EST — [Amwell® to Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/AMWL/amwell-to-participate-in-upcoming-investor-conference-c285d2c6) — Source: American Well
- 2026-05-05 20:05 EST — [Amwell® Announces Results for First Quarter 2026](https://biopharmsignal.com/news/AMWL/amwell-announces-results-for-first-quarter-2026-1abdf658) — Source: American Well
- 2026-04-20 20:05 EST — [Amwell® to report first quarter 2026 operating results](https://biopharmsignal.com/news/AMWL/amwell-to-report-first-quarter-2026-operating-results-ae059d6a) — Source: American Well
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)